The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of research elucidating acquired resistance mechanisms to PD-(L)1 inhibitors in patients with non-small cell lung cancer (NSCLC). Acquired mutations in STK11, KEAP1 and SMARCA4 were identified in a subset of patients and acquired deleterious mutations in the beta 2-microglobulin (B2M) gene were additionally found, which can impact response to immune checkpoint inhibitors. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
